JP7680032B2 - Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 - Google Patents

Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 Download PDF

Info

Publication number
JP7680032B2
JP7680032B2 JP2021556481A JP2021556481A JP7680032B2 JP 7680032 B2 JP7680032 B2 JP 7680032B2 JP 2021556481 A JP2021556481 A JP 2021556481A JP 2021556481 A JP2021556481 A JP 2021556481A JP 7680032 B2 JP7680032 B2 JP 7680032B2
Authority
JP
Japan
Prior art keywords
tcr
cells
seq
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556481A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020188348A5 (https=
JP2022525925A5 (https=
JP2022525925A (ja
Inventor
クーコス，ジョージ
アーヴィング，メリタ
ゾーテ，ヴィンセント
ミシュラン，オリヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of JP2022525925A publication Critical patent/JP2022525925A/ja
Publication of JPWO2020188348A5 publication Critical patent/JPWO2020188348A5/ja
Publication of JP2022525925A5 publication Critical patent/JP2022525925A5/ja
Application granted granted Critical
Publication of JP7680032B2 publication Critical patent/JP7680032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
JP2021556481A 2019-03-18 2020-03-17 Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 Active JP7680032B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (4)

Publication Number Publication Date
JP2022525925A JP2022525925A (ja) 2022-05-20
JPWO2020188348A5 JPWO2020188348A5 (https=) 2023-03-17
JP2022525925A5 JP2022525925A5 (https=) 2023-03-17
JP7680032B2 true JP7680032B2 (ja) 2025-05-20

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556481A Active JP7680032B2 (ja) 2019-03-18 2020-03-17 Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用

Country Status (7)

Country Link
US (2) US12473346B2 (https=)
EP (1) EP3941939A2 (https=)
JP (1) JP7680032B2 (https=)
CN (1) CN113906140B (https=)
AU (1) AU2020243431B2 (https=)
CA (1) CA3134102A1 (https=)
WO (1) WO2020188348A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4217738A1 (en) * 2020-09-27 2023-08-02 Genentech, Inc. High throughput multiparametric immune cell engager screening assay
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537743A (ja) 2004-05-19 2007-12-27 メディジーン リミテッド Ｔ細胞レセプターを改善する方法
JP2008509090A (ja) 2004-05-19 2008-03-27 メディジーン リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5617900A (en) 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537743A (ja) 2004-05-19 2007-12-27 メディジーン リミテッド Ｔ細胞レセプターを改善する方法
JP2008509090A (ja) 2004-05-19 2008-03-27 メディジーン リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZOETE, V et al.，Structure-based, rational design of T cell Receptors ，Front Immunol.，vol.4，2013年09月12日，268

Also Published As

Publication number Publication date
AU2020243431A1 (en) 2021-09-30
EP3941939A2 (en) 2022-01-26
US12473346B2 (en) 2025-11-18
WO2020188348A2 (en) 2020-09-24
US20220152109A1 (en) 2022-05-19
JP2022525925A (ja) 2022-05-20
US20260103503A1 (en) 2026-04-16
CN113906140B (zh) 2025-01-28
CA3134102A1 (en) 2020-09-24
WO2020188348A3 (en) 2020-12-17
CN113906140A (zh) 2022-01-07
AU2020243431B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
JP7527049B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
US20240141041A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
JP7680032B2 (ja) Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用
US12275787B2 (en) Chimeric antigen receptors (CARs), compositions and methods thereof
JP7450892B2 (ja) Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
EP3995142A2 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
JP2017522893A (ja) Ｒｏｒ１特異的多重鎖キメラ抗原受容体
JP2019536452A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
KR20230088333A (ko) 입양 세포 요법을 위한 표적화된 공동자극을 제공하는 수용체
KR20230008915A (ko) 개선된 t 세포 조성물
RS66264B1 (sr) Genska terapija
US20220267425A1 (en) Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
US20230030680A1 (en) Chimeric gmcsf-il18 receptor
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
US20250346649A1 (en) Zip cytokine receptors
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
HK40058918A (en) A2/ny-eso-1 specific t cell receptors and uses thereof
HK40058918B (zh) A2/ny-eso-1特异性t细胞受体及其用途
US20240207319A1 (en) Compositions and methods for immunotherapy
HK40100191A (zh) 用於同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞
WO2024238938A1 (en) Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy
HK40073530B (zh) 用於免疫治疗的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250428

R150 Certificate of patent or registration of utility model

Ref document number: 7680032

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150